close

Second phase II study for zilebesiran, an RNAi therapeutic for the treatment of hypertension

Second phase II study for zilebesiran, an RNAi therapeutic for the treatment of hypertension Alnylam Pharmaceuticals, a leading RNAi therapeutics company, has initiated KARDIA-2 (NCT05103332), a global Phase 2 study to evaluate the efficacy and safety of zilebesiran (formerly known as ALN-AGT), an investigational subcutaneous RNAi therapeutic targeting liver-expressed angiotensinogen…..